Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

Full description

Bibliographic Details
Published in:	EJC Paediatric Oncology
Main Authors:	Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Subjects:	Acute lymphoblastic leukemia Imatinib High-dose methotrexate Clearance Pediatric
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772610X23001113

Similar Items

The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy
by: Yi-Lun Wang, et al.
Published: (2025-10-01)

Retrospective evaluation and prediction of clearance and toxicity of high dose methotrexate in childhood acute lymphoblastic leukemia patients
by: Yuxia Shan, et al.
Published: (2021-04-01)

High-Dose Methotrexate: Treatment Experience in Patient with B-cell Philadelphia-Positive Acute Lymphoblastic Leukemia
by: Avinash Khadela, et al.
Published: (2021-01-01)

The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia
by: N. Oosterom, et al.
Published: (2020-09-01)

SLC19A1 polymorphism and serum methotrexate in patients with acute lymphoblastic leukemia
by: Beuy Joob, et al.
Published: (2018-01-01)

Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia
by: Jung Yoon Choi, et al.
Published: (2024-11-01)

Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing
by: Zhongbo Hu, et al.
Published: (2024-11-01)

Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia
by: Nirmalya Roy Moulik, et al.
Published: (2016-01-01)

High-Dose Methotrexate-Induced Idiopathic Intracranial Hypertension in Infant Acute Lymphoblastic Leukemia
by: Yazhi Zhang, et al.
Published: (2020-06-01)

Intravitreal methotrexate in type B lymphoblastic leukemia—Case Report
by: Maria Isabel Maya Naranjo, et al.
Published: (2023-08-01)

Acute Lymphoblastic Leukemia and Seizures
by: J Gordon Millichap
Published: (1995-08-01)

Differential metabolomic pathway analysis in Malaysian childhood acute lymphoblastic leukemia patients treated with high-dose methotrexate
by: Rizal Husaini Razali, et al.
Published: (2024-09-01)

Association of microRNA Polymorphisms with Toxicities Induced by Methotrexate in Children with Acute Lymphoblastic Leukemia
by: Vasiliki Karpa, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
by: Wang Cao, et al.
Published: (2022-12-01)

Evaluation of Relationship of the Methylene Tetrahydrofolate Reductase Enzyme Polymorphisms with Serum Methotrexate Concentration and Toxicity in Acute Lymphoblastic Leukemia Patients Treated with High Dose Methotrexate Infusion
by: Manjusha Sajith, et al.
Published: (2020-07-01)

Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines
by: Rafael Renatino Canevarolo, et al.
Published: (2022-12-01)

Erratum: Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines
by: Frontiers Production Office
Published: (2023-03-01)

Increased survival rate in acute lymphoblastic leukemia treated with methotrexate by DR5 and Caspase-8 in hyperglycemic conditions
by: Kosar Kiafar, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China
by: Min Chen, et al.
Published: (2023-06-01)

Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis
by: Chang Jian, et al.
Published: (2023-08-01)

The influence of detoxification agents on the intensity of side effects caused by medium-high doses of methotrexate in children with acute lymphoblastic leukemia: Case series
by: Šumar Jovana S., et al.
Published: (2014-01-01)

The role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
by: T. T. Valiev, et al.
Published: (2024-12-01)

Association between ABCB1 C3435 T polymorphism- and methotrexate-related toxicity in pediatric acute lymphoblastic leukemia: a meta-analysis
by: Xuefen Yan, et al.
Published: (2025-12-01)

Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia
by: Min Zhan, et al.
Published: (2023-06-01)

Predictors Associated with Delayed Methotrexate Clearance among Patients with Haematological Malignancies
by: Muhammad Nasri Yusoff, et al.
Published: (2025-07-01)

The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol
by: Stefania Braidotti, et al.
Published: (2025-02-01)

Association of <i>SLC19A1</i> Gene Polymorphisms and Its Regulatory miRNAs with Methotrexate Toxicity in Children with Acute Lymphoblastic Leukemia
by: Vasiliki Karpa, et al.
Published: (2024-10-01)

Methotrexate-Mediated Arachnoiditis in a Child with Acute Lymphoblastic Leukemia
by: Sırma Karamercan, et al.
Published: (2022-11-01)

Recurrence of methotrexate-induced leukoencephalopathy after methotrexate rechallenge: A case report and literature review
by: Ammar AlKawi, MD, et al.
Published: (2023-03-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Imatinib-Induced Psoriasis
by: Figen Atalay, et al.
Published: (2013-06-01)

Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia
by: Ewa Pustelnik, et al.
Published: (2023-10-01)

Population Pharmacokinetics and Covariate Analysis of Methotrexate in Pediatric Acute Lymphoblastic Leukemia
by: Yu B, et al.
Published: (2025-09-01)

Detecting Methotrexate in Pediatric Patients Using Artificial Neural Networks
by: Alejandro Medina Santiago, et al.
Published: (2024-12-01)

A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate
by: Reed DR, et al.
Published: (2019-08-01)

Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
by: Ajibade Ashaye, et al.
Published: (2025-04-01)

Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia
by: Lian LJ, et al.
Published: (2020-11-01)

Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases
by: Nicolò Peccatori, et al.
Published: (2025-06-01)

The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment
by: Shoshana Rudin, et al.
Published: (2017-04-01)